RILUTEK
Pronunciation: RIL-yoo-zoel


What it isGlutamate release inhibitor; amyotrophic lateral sclerosis.
Why this oneIt extends survival by a few months, and it was the first disease-modifying agent in ALS.
What limits itHepatotoxicity requires monthly liver tests initially. Take on an empty stomach; CYP1A2-dependent, so smoking lowers levels.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Amyotrophic lateral sclerosis (ALS) | adult | 50 mg BID | 50 mg BID | 50 mg BID |
Renal Undefined
Hepatic Mild-moderate (Child-Pugh A/B): increased exposure, higher risk of adverse reactions; severe: unknown. Not recommended if baseline aminotransferases >5x ULN or evidence of liver dysfunction
Available strengths
Pregnancy Based on animal data, may cause fetal harm
Lactation Unknown if excreted in human milk; detected in rat milk
| Strength | #/mo | generic $/mo | CostPlus | |
|---|---|---|---|---|
| 50 mg | tab | 60 BID | $17.60 | offered |
Generic entry2003
NO BOXED WARNINGS
Principal riskHepatotoxicity needing monthly liver tests initially
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Open Riluzole in the interactive console ↗
